Drug Resistant Epilepsy Clinical Trials

29 recruitingLast updated: June 18, 2026

There are 29 actively recruiting drug resistant epilepsy clinical trials across 11 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, Paris, France, Lille, France. Updated daily from ClinicalTrials.gov.


Drug Resistant Epilepsy Trials at a Glance

29 actively recruiting trials for drug resistant epilepsy are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Not Applicable with 18 trials, with the heaviest enrollment activity in Boston, Paris, and Lille. Lead sponsors running drug resistant epilepsy studies include Hospices Civils de Lyon, NaviFUS Corporation, and Xuanwu Hospital, Beijing.

Browse drug resistant epilepsy trials by phase

Treatments under study

About Drug Resistant Epilepsy Clinical Trials

Looking for clinical trials for Drug Resistant Epilepsy? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Drug Resistant Epilepsy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Drug Resistant Epilepsy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Not Applicable

Epileptogenic Network Visualisation With Advanced MRI

Drug Resistant Epilepsy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain80 enrolled1 locationNCT06059157
Recruiting

Evaluate the effectiveness of personalised Deep Brain Stimulation

Drug Resistant Epilepsy
The Alfred20 enrolled1 locationACTRN12626000569303
Recruiting
Not Applicable

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

EpilepsyDravet SyndromeDrug Resistant Epilepsy+1 more
Hospices Civils de Lyon30 enrolled1 locationNCT07013331
Recruiting
Not Applicable

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

EpilepsyDrug Resistant EpilepsyEpilepsy, Temporal Lobe+1 more
NaviFUS Corporation16 enrolled1 locationNCT06492720
Recruiting
Phase 1Phase 2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

seizureEpilepsyDrug Resistant Epilepsy+2 more
NaviFUS Corporation8 enrolled3 locationsNCT06388707
Recruiting
Not Applicable

MiCrobiota-gut-brain Axis in Resistant Epilepsy

EpilepsyDrug Resistant EpilepsyGut Microbiota
Niguarda Hospital120 enrolled1 locationNCT07010445
Recruiting

Neurosurgical Outcome Network

DepressionTrigeminal NeuralgiaObsessive-Compulsive Disorder+20 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta4,500 enrolled27 locationsNCT06724029
Recruiting
Not Applicable

Infrared Photobiomodulation in Humans With Epilepsy

Drug Resistant Epilepsy
Beth Israel Deaconess Medical Center13 enrolled1 locationNCT07145489
Recruiting
Not Applicable

MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy

EpilepsyDrug Resistant EpilepsyCandidates for Surgical Treatment
Hospices Civils de Lyon100 enrolled1 locationNCT03893916
Recruiting

Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain

PediatricsDrug Resistant EpilepsyEpilepsies, Focal
Fondation Ophtalmologique Adolphe de Rothschild82 enrolled1 locationNCT03268824
Recruiting
Not Applicable

Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

EpilepsyDrug Resistant Epilepsy
Assistance Publique Hopitaux De Marseille60 enrolled7 locationsNCT06334952
Recruiting
Not Applicable

Goals for Epilepsy Clinic Visits Trial

Drug Resistant Epilepsy
University of Michigan152 enrolled1 locationNCT05928598
Recruiting
Not Applicable

Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

Drug Resistant Epilepsy
Brigham and Women's Hospital10 enrolled1 locationNCT03868293
Recruiting
Not Applicable

Focused Ultrasound for Drug-resistant Epilepsy

Drug Resistant EpilepsyDrug Refractory EpilepsyFocused Ultrasound+2 more
Taipei Veterans General Hospital, Taiwan20 enrolled1 locationNCT06292494
Recruiting

Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients

Autism Spectrum DisorderDrug Resistant EpilepsyChronic Migraine+1 more
Danone Nutricia SpA Società Benefit100 enrolled3 locationsNCT06309251
Recruiting
Phase 2

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Refractory EpilepsyMedically refractory epilepsyDrug Resistant Epilepsy
Madeline Fields8 enrolled1 locationNCT05019885
Recruiting
Not Applicable

Electroclinical Correlation of Anxiety

Generalized Anxiety DisorderDrug Resistant EpilepsyAnxiety Disorder
University Hospital, Bordeaux30 enrolled1 locationNCT05393518
Recruiting
Not Applicable

StereoEEG Motor Neuronal Potentials Decoding

Drug Resistant EpilepsyBrain-Computer Interfaces
Research Center of Neurology, Russia30 enrolled1 locationNCT06432907
Recruiting
Not Applicable

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Drug Resistant EpilepsyEpilepsy, Temporal Lobe
Genovate-NaviFUS (Australia) Pty Ltd.18 enrolled1 locationNCT05947656
Recruiting

Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology

Magnetic Resonance ImagingDrug Resistant EpilepsyElectroencephalogram (EEG)
Xijing Hospital50 enrolled1 locationNCT06557720